Commoney Wise
  • News
  • Politics
  • Business
  • Finance
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Futures
    • Forex
  • Crypto
  • Price Index
    • Stocks
    • Cryptocurrency
    • Commodities
    • Forex
  • Videos
  • Login
  • Register

  Breaking
Gas prices dip as economy recovers: AAA February 8, 2023
Saudi Arabia partners with The Sandbox for future metaverse plans February 8, 2023
Pound Sterling Price News and Forecast: GBP/USD climbs to fresh weekly top February 8, 2023
SocGen favours prudence over high shareholder return before CEO change February 8, 2023
Gold prices on track to rise for third day as markets cheer dovish Powell February 8, 2023
Next
Prev

en English
en Englishes Españolde Deutschfr Françaisit Italianopt Portuguêsru Русскийzh-CN 简体中文hi हिन्दीja 日本語
Casino
  • News
  • Politics
  • Business
  • Finance
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Futures
    • Forex
  • Crypto
  • Price Index
    • Stocks
    • Cryptocurrency
    • Commodities
    • Forex
  • Videos
No Result
View All Result
Commoney Wise
Casino
  • News
  • Politics
  • Business
  • Economy
  • Finance
  • Investing
  • Markets
  • Crypto
  • Tech
  • Videos
Home Business

Amgen close to deal to buy Horizon Therapeutics for $20bn

Staff by Staff
December 11, 2022
in Business
0 0
A A
0

Amgen is close to a deal to acquire Horizon Therapeutics in a transaction worth as much as $20bn, according to sources familiar with the matter, as a sell-off in healthcare stocks creates attractive targets.

A deal between the California-based biotech and Horizon, which is headquartered in Ireland, would mark the largest pharmaceutical transaction since AstraZeneca bought Alexion for $39bn last year.

The takeover would give Amgen access to Horizon’s pipeline of drugs for rare autoimmune and inflammatory diseases, including its blockbuster treatment Tepezza.

Horizon said last month that it was in takeover talks with three potential suitors, among them Johnson & Johnson and Sanofi. The French drugmaker said on Sunday that it had evaluated the deal and decided that the price was not right.

The potential deal comes hot on the heels of Amgen’s $3.7bn acquisition of ChemoCentryx, a San Carlos, California-based company that develops drugs for inflammatory and autoimmune diseases as well as cancer.

Analysts have been predicting a boom in mergers and acquisitions in the pharmaceutical sector as valuations have come down in the worst biotech sell-off since the early 2000s. Shares in Horizon had fallen 27 per cent from the start of the year until late November, when the company confirmed it was engaged in preliminary deal discussions.

While there has been a broader slowdown in M&A this year, drugmakers have been busy putting their large piles of cash to work as they seek to replenish their drug pipelines.

Johnson & Johnson announced in November it had struck a deal to acquire cardiovascular technology group Abiomed for $16.6bn, while Pfizer said in May it had agreed to buy US biotech Biohaven Pharmaceuticals for $11.6bn. 

Still, 2022 has so far been a quieter year for M&A, with overall pharmaceutical and life sciences deal value down by 49 per cent year on year, and volumes falling by 28 per cent, according to data compiled by PwC.

Tim Walbert, Horizon’s chief executive, suffers from an autoimmune condition himself, and previously led the global development of Abbvie’s blockbuster Humira.

Horizon received regulatory approval for Tepezza in January 2020. In the third quarter, it had net sales for the drug of $490.9mn, guiding to a high teens percentage growth rate for the full year. In total, it forecasts net sales of between $3.59bn and $3.61bn, and adjusted earnings before interest, tax, depreciation and amortisation of $1.32bn to $1.34bn for 2022.

The company has an extensive pipeline of drugs targeting autoimmune diseases including rheumatoid arthritis, lupus, atopic dermatitis, and gout.

The deal was first reported by the Wall Street Journal.

Read the full article here

ShareTweetSharePinShareSendShare
https://www.madmoneycasino.com/?faff=667&sub=DemCasino

Related Articles

Business

Gas prices dip as economy recovers: AAA

February 8, 2023
Business

DIY multi-strategy hedge funds

February 8, 2023
Business

Biden Labor Secretary Marty Walsh expected to step down for job with NHL Players’ Association

February 8, 2023
Business

Popeyes re-enters China to take on KFC in fried-chicken fight

February 8, 2023
Business

Disney’s Iger to face investors as he contends with activist, ESPN’s future, streaming status

February 8, 2023
Business

Republicans to grill ex-Twitter executives over handling of Hunter Biden story

February 8, 2023
Load More

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Commoney Wise

Commoney Wise is your one stop news website for the latest finance, business and crypto news, follow us to get the news that matters to your minute by minute.

Our Other Brands Kronosslott, Commoneywise, Demcasino.de, SportsExtremes.tv, Slotgamesusawwr, Coin Desk Times, Kingsofgolf.be

Topics

Business Commodities Crypto Economy Finance Forex Futures Investing Markets News Politics Stocks Tech Videos

Get Informed

The most important world news and events of the day

Be the first to know latest important news & events directly to your inbox.

By signing up, I agree to our TOS and Privacy Policy.

  • Privacy
  • Terms
  • Press
  • Advertise
  • Contact

© 2022 Commoney Wise. All Rights Reserved.

No Result
View All Result
  • News
  • Politics
  • Business
  • Finance
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Futures
    • Forex
  • Crypto
  • Price Index
    • Stocks
    • Cryptocurrency
    • Commodities
    • Forex
  • Videos

© 2022 Commoney Wise. All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.